Frank George Njoroge

Title: Frank George Njoroge: Innovator in Cancer Treatment

Introduction

Frank George Njoroge is a notable inventor based in Carmel, IN (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. With a total of 2 patents, Njoroge's work focuses on inhibitors that target specific pathways involved in cancer progression.

Latest Patents

Njoroge's latest patents include groundbreaking inventions such as CD73 inhibitors. This invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer. Another significant patent involves 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, which are formulated for use as AICARFT inhibitors in the treatment of cancers.

Career Highlights

Frank George Njoroge is currently employed at Eli Lilly and Company, where he continues to advance his research in oncology. His work has been instrumental in developing new therapeutic options for patients battling cancer.

Collaborations

Njoroge collaborates with esteemed colleagues, including Robert Dean Dally and Maria Cristina Garcia Paredes. These partnerships enhance the innovative potential of his research and contribute to the overall success of their projects.

Conclusion

Frank George Njoroge is a dedicated inventor whose work in cancer treatment is paving the way for new therapeutic strategies. His patents reflect a commitment to improving patient outcomes through innovative science.